Hartmuth C. Kolb, PhD

Dr. Hartmuth Kolb earned a PhD in Organic Chemistry from Imperial College London (1991). After Ciba-Geigy (1993), he became VP of Chemistry at Coelacanth (1997), collaborating with K. Barry Sharpless to pioneer Click Chemistry and first-authoring its inaugural paper (recognized by the 2022 Nobel Prize to Sharpless, Meldal, and Bertozzi). He later led Siemens Biomarker Research, applying click methods to PET tracer discovery, including [18F]-T807 (Flortaucipir/Tauvid), the first FDA-approved tracer for imaging tau pathology in Alzheimer’s disease. Joining Johnson & Johnson in 2014, he advanced PET tracers and precision neuroscience, and his lab developed one of the first p217Tau blood tests. In March 2024, he became CSO of EBG to focus on CNS imaging tracers and is a Visiting Professor at the University of Wisconsin–Madison. Dr. Kolb has 100+ peer-reviewed papers and 40+ patents.